# Christof von Kalle

Source: https://onco.cc/people/christof-von-kalle/  
OnCo record `christof-von-kalle` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Gene therapy pioneer who developed methods to track vector integration in treated patients.

## Summary

Christof von Kalle is Director of the Clinical Study Center at the Berlin Institute of Health at Charité Universitätsmedizin Berlin. His specialisms are gene therapy, cell therapy safety and translational research, with links to CAR-T and in vivo CAR-T technologies. He is a gene therapy pioneer who developed integration-site analysis to track vector integration in treated patients, methods that revealed insertional mutagenesis in early gene therapy trials. He led translational oncology at NCT Heidelberg before moving to Berlin. His recent papers apply deep learning to histology, including a review of gastrointestinal cancer classification and studies predicting lymph node status from tumour histology in colorectal and prostate cancer. His publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Director, Clinical Study Center, Berlin Institute of Health at Charité
- Specialisms: Gene therapy; Cell therapy safety; Translational research

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=von%20Kalle%20C%5BAuthor%5D%20gene%20therapy%20integration

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/), [In vivo CAR-T](https://onco.cc/technologies/in-vivo-car-t/)
- institutions: [Charité Universitätsmedizin Berlin](https://onco.cc/institutions/charite/)

---
JSON: https://onco.cc/api/v1/entities/christof-von-kalle.json